MDT

98.84

+0.35%↑

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

MDT

98.84

+0.35%↑

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

MDT

98.84

+0.35%↑

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

MDT

98.84

+0.35%↑

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

MDT

98.84

+0.35%↑

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

Home・Aandelen Lijst・Atossa Genetics Inc

Atossa Genetics Inc

Gesloten

0.57 -3.39

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.57

Max

0.6

Belangrijke statistieken
By Trading Economics
Inkomsten	-269K -8.7M
Werknemers	15
EBITDA	-269K -8.7M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+889.06% upside

Dividenden
By Dow Jones
Volgende Winsten	24 mrt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-24M 84M
Vorige openingsprijs	3.96
Vorige sluitingsprijs	0.57

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

0.7955 / 0.898 Steun & Weerstand

Atossa Genetics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 jan 2026, 18:44 UTC

Belangrijke Marktbewegers

Agenus Falls After $141 Million Zydus Deal Closes

15 jan 2026, 17:51 UTC

Belangrijke Marktbewegers

Galaxy Digital Climbs on Texas Data-Center Expansion Approval, Tokenized CLO Issuance

15 jan 2026, 17:25 UTC

Belangrijke Marktbewegers

ASML Exceeds $500 Billion in Market Value on TSMC's Blockbuster Spending Plans -- Update

15 jan 2026, 23:48 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

15 jan 2026, 23:48 UTC

Marktinformatie

Nikkei May Decline as Enthusiasm Over Election Eases -- Market Talk

15 jan 2026, 23:40 UTC

Marktinformatie

Gold Edges Lower Amid Abating Geopolitical Risks -- Market Talk

15 jan 2026, 23:11 UTC

Marktinformatie

Global Equities Roundup: Market Talk

15 jan 2026, 23:11 UTC

Marktinformatie

Ryman Healthcare's Resales Remain Key Concern -- Market Talk

15 jan 2026, 23:01 UTC

Marktinformatie

New Zealand's Economy Enters An Upswing -- Market Talk

15 jan 2026, 22:56 UTC

Marktinformatie

Winsten

Catalyst Metals Delivers a Beat With Record Gold Output -- Market Talk

15 jan 2026, 22:51 UTC

Marktinformatie

James Hardie's Plant Closures Could Boost Profit by 2%-3% -- Market Talk

15 jan 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Verizon Gets Final California Approval to Secure $9.6 Billion Frontier Deal -- WSJ

15 jan 2026, 21:50 UTC

Marktinformatie

Winsten

Financial Services Roundup: Market Talk

15 jan 2026, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Energy & Utilities Roundup: Market Talk

15 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

15 jan 2026, 21:27 UTC

Winsten

BlackRock Caps 2025 With Record $14 Trillion in Assets -- 3rd Update

15 jan 2026, 21:15 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Global Commodities Roundup: Market Talk

15 jan 2026, 21:11 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

15 jan 2026, 21:11 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Canada Antitrust Watchdog Confirms Review of Canadian Energy Deal -- Market Talk

15 jan 2026, 20:10 UTC

Marktinformatie

U.S. Natural Gas Futures Settle Mixed -- Market Talk

15 jan 2026, 20:04 UTC

Winsten

These Stocks Are Today's Movers: TSMC, ASML, Goldman, Morgan Stanley, BlackRock, Coinbase, Sandisk, and More -- Barrons.com

15 jan 2026, 20:03 UTC

Marktinformatie

Oil Futures Fall As Iran Risk Premium Fades -- Market Talk

15 jan 2026, 19:26 UTC

Marktinformatie

Silver Closes at Fresh High -- Market Talk

15 jan 2026, 18:29 UTC

Belangrijke Marktbewegers

Agenus Falls After $141M Zydus Deal Closes

15 jan 2026, 18:20 UTC

Winsten

Wall Street Powers Nation's Biggest Banks to Record Year -- WSJ

15 jan 2026, 17:56 UTC

Marktinformatie

Winsten

U.S. Bank Results Look Encouraging for European Peers -- Market Talk

15 jan 2026, 17:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Auto & Transport Roundup: Market Talk

15 jan 2026, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

15 jan 2026, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

15 jan 2026, 17:02 UTC

Acquisities, Fusies, Overnames

KBC Group Completes Acquisition of 98.45% Stake in 365.bank From J&T Finance Group

Peer Vergelijking

Prijswijziging

Atossa Genetics Inc Prognose

Koersdoel

By TipRanks

889.06% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6.33 USD 889.06%

Hoogste 8 USD

Laagste 4 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Atossa Genetics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Atossa Genetics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.7955 / 0.898Steun & Weerstand

Recent bullish events outweigh bearish events.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Atossa Genetics Inc

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.